Newsletter March 2024 No.220
Top News
Held "JPMA Presidents Press Conference" Toward a Nation Driven by Innovation
On February 15, 2024, the "JPMA Presidents' Press Conference" was held at Bellesalle Iidabashi Station (Chiyoda-ku, Tokyo) in a hybrid format of on-site and online participation. JPMA Chairman Hiroaki Ueno opened the press conference by expressing his condolences for the Noto Peninsula Earthquake of 2024, which occurred on January 1, 2024, and then gave a presentation titled "Toward a Nation Dynamic in Innovation. In his presentation, he explained the importance of proper evaluation of innovation and the direction of the pharmaceutical industry's efforts to strengthen Japan's drug discovery capabilities, and engaged in a lively Q&A session with the 35 members of the press from 21 companies who attended the event. Below is a summary of Chairman Ueno's presentation and the Q&A session.
Topics
- JPMA Rare Disease Day 2024 Symposium" was held
- The 4th Japan-Vietnam Joint Symposium" will be held
- The 5th ICH Forum: ICH Quality Guideline Update
- Joint Conference on Global Health 2023" held Co-hosted symposium on "Drug Resistance (AMR) as a Global Health Issue
- Held "Regular Meeting with the European Federation of Pharmaceutical Industries and Associations (EFPIA)
- Regular meeting with the German Association of the Research-based Pharmaceutical Industry (vfa)" was held
- The "Regular Meeting with the French Association of the Pharmaceutical Industry (Leem)" was held
- CMC Strategy Forum Japan 2023" will be held
- Workshop on "Next Generation Adverse Reaction Case Evaluation" was held.
Policy Research Institute
Comparison of New Drug Approval Status and Review Periods in Japan, the U.S., and Europe (2022)
From JPMA
Aiming for a Nation Driven by Innovation